Weekly shot could replace daily growth hormone for short kids
NCT ID NCT07260500
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new weekly growth hormone injection (PEG-rhGH) against the standard daily shot in 72 short children born small for gestational age. The children, aged 3 and up with no puberty signs, will receive either a low or high weekly dose or a daily dose for 26 weeks. The main goal is to see how fast they grow, aiming to find a more convenient treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PEGylated recombinant human growth hormone (PEG-rhGH, Jintrolong®) and daily recombinant human growth hormone (hGH, Jintropin®)
- What this could lead to
- If successful, this could offer a more convenient once-weekly growth hormone injection for children born small for gestational age who are short, potentially improving growth with fewer injections.
- What could go wrong
- This is an early phase 2 trial with only 72 children, so results may not confirm effectiveness or safety. The weekly injection may not work as well as the daily one, and side effects like injection site reactions or growth-related issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SHORT STATURE CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.